The success of Sym023 promoted the studies evaluating the preliminary efficacy of the combined Sym021 (anti-PD-1), Sym022 (anti-LAG-3), and Sym023 in tumor therapies (NCT04641871 and NCT03311412). Here, PDCD1 is linked to neoplasm.